Abstract
Aim: Expression of PD-1 on T/B cells regulates peripheral tolerance and autoimmunity. Binding of PD-1 to its ligand, PD-L1, leads to protection against self-reactivity. In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor signal transduction. PD-L1 and PD-1 blockade using antibodies are in human clinical trials as an alternative cancer treatment modality. Areas covered: We describe the role of PD-1/PD-L1 in disease in the context of autoimmunity, neurological disorders, stroke and cancer. Conclusion: For immunotherapy/vaccines to be successful, the expression of PD-L1/PD-1 on immune cells should be considered, and the combination of checkpoint inhibitors and vaccines may pave the way for successful outcomes to disease.
Original language | English |
---|---|
Pages (from-to) | 149-161 |
Number of pages | 13 |
Journal | Immunotherapy |
Volume | 10 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2018 |
Externally published | Yes |
Keywords
- PD-1
- PD-L1
- autoimmune disease
- cancer
- neurological disease
- vaccines
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology